Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Friday, May 10, 2024 | Back issues
Courthouse News Service Courthouse News Service

Diabetes Drugs

A federal court in California refused to grant summary judgment to brand and generic manufacturers of the type 2 diabetes Glumetza in an antitrust class action accusing the pharmaceutical firms of plotting to hike up the price of the drug.

SAN FRANCISCO — A federal court in California refused to grant summary judgment to brand-name and generic manufacturers of the type 2 diabetes Glumetza in an antitrust class action accusing the pharmaceutical firms of plotting to hike up the price of the drug. 

Categories / Business, Consumers, Health

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...